Protagonist's CEO said J&J reported more than 20,000 prescriptions for Icotide, and that J&J guided toward breaking out its sales as a line item sometime in 2027. He also said over half a billion of milestones are pending. A decision on a second indication for the oral candidate is planned for the second half of next year, assuming enrollment proceeds at a decent pace.
PTGX · Protagonist Therapeutics, Inc
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Price & Indicators
Up next
Latest documents
Protagonist Therapeutics, Inc. reported net income of $220,015 thousand for the three months ended September 30, 2026, driven by $274.4 million in collaboration revenue following MIMRYLO approval and Takeda opt-out payments; cash and marketable securities reached approximately $834.6 million.
Protagonist Therapeutics reported that MIMRYLO’s FDA approval triggered $275 million in payments, third-quarter net income was $220.0 million, and the Board authorized a $300 million share repurchase program.
Metrics snapshot
Useful current figures from the complete screener profile.
Quarterly results
* Q4 derived as the full year minus Q1 to Q3.
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders SellIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
PTGX
this stock
Protagonist Therapeutics, Inc
|
$8.30B | +45.6% | -89.4% | 26.9 | 15.7% |
|
VRTX
Vertex Pharmaceuticals Inc
|
$136.01B | +18.3% | +46.2% | 34.5 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$97.81B | +22.5% | +20.8% | 20.9 | 2.1% |
|
MRNA
Moderna, Inc.
|
$79.63B | +567.3% | +4.3% | — | 8.2% |
|
CSLLY
Csl Ltd
|
$63.15B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every section- Filed
- Nov 17, 2026
- This year
- 16
Protagonist's CEO said J&J reported more than 20,000 prescriptions for Icotide, and that J&J guided toward breaking out its sales as a line item sometime in 2027. He also said over half a billion of milestones are pending. A decision on a second indication for the oral candidate is planned for the second half of next year, assuming enrollment proceeds at a decent pace.
ViewPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| PTGX | -5.7% | -7.9% | +27.7% | -12.2% | +45.6% |
| SPY | -3.9% | -5.6% | -3.5% | -3.4% | +7.1% |
| vs SPY | -1.8% | -2.4% | +31.2% | -8.8% | +38.5% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.